Back to search results

Vaccine Responses After CAR-T Treatment for Myeloma and Lymphoma

This study looks at how well vaccines work in people with multiple myeloma or non-Hodgkin lymphoma after they've had CAR-T cell therapy. Researchers want to see if CAR-T therapy affects your body's ability to fight off diseases like measles, mumps, and rubella, as well as pneumonia and tetanus. You would be eligible if you are at least 18 years old and have a confirmed diagnosis of multiple myeloma, diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, or chronic lymphocytic leukemia. The main goal is to see if your immunity (your body's protection against diseases) is still strong up to 12 months after your CAR-T cell infusion. The current recruitment status is unclear.

Study design
This is an observational study with a planned enrollment of 45 participants. It is not specified whether it is randomized or blinded.
What's involved
You may receive up to three doses of pneumococcal and/or tetanus vaccine. You will have blood samples collected and your medical records reviewed throughout the study.
Compensation
Not stated in the trial record.
Follow-up
Your immunity will be measured for up to 12 months after your CAR-T cell infusion.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06784167

Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment

Recruiting
Not specifiedAges 18+Observational
OHSU Knight Cancer Institute
~45 participants
Updated 2025-09-15 on ClinicalTrials.gov
What's tested:Non-Interventional Study

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Preserved immunity
Measured over Up to 12 months after CAR-T cell infusion

Conditions

Chronic Lymphocytic Leukemia
Diffuse Large B-Cell Lymphoma
Follicular Lymphoma
Mantle Cell Lymphoma
Multiple Myeloma
Primary Mediastinal Large B-Cell Lymphoma
Small Lymphocytic Lymphoma

Explore related trials

Chronic Lymphocytic LeukemiaDiffuse Large B-Cell LymphomaFollicular LymphomaMantle Cell LymphomaMultiple MyelomaPrimary Mediastinal Large B-Cell LymphomaSmall Lymphocytic Lymphoma

Where it's being run

1 sites across 1 states
Oregon1

Study leadership

  • Amrita Desai · PRINCIPAL_INVESTIGATOR · OHSU Knight Cancer Institute

Who to contact

Amrita Desai
[email protected]
503-494-8534
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

\* Willingness to provide written informed consent before any study-specific procedures or activities are performed
Age ≥ 18 years of age, at the time of consent
Documented, histologically or cytologically confirmed diagnosis of multiple myeloma (MM), diffuse large B cell lymphoma (DLBCL),follicular lymphoma (FL), mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL), or small lymphocytic lymphoma (SLL), or primary mediastinal B cell lymphoma (PMBL). All number of prior lines of therapy are allowed
History of prior vaccination against common VPD
Approved by managing physician for CAR-T therapy, with preparative conditioning planned within the next 90 days
Approved by managing physician for revaccination against Streptococcus pneumoniae or tetanus

Exclusion

\* Ongoing use of immunosuppressive agents or plans for immunosuppressive therapy that would interfere with interpretation of study endpoints
Uncontrolled, intercurrent illness including, but not limited to, systemic infection, symptomatic congestive heart failure, unstable angina pectoris, or psychiatric illness/social situations that would limit compliance with study requirements or make the study procedures unadvisable

What this trial measures

  • Preserved immunityUp to 12 months after CAR-T cell infusion

    Will be defined as titers that meet the definition of positive both pre- and post-CAR-T cell infusion. The proportion of subjects who have preserved immunity to each VPD will be estimated with an exact 95% confidence interval.